- Conditions
- Bleeding
- Interventions
- Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG
- Biological · Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cypress, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Volunteers
- Interventions
- PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo
- Combination Product · Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Tempe, Arizona